Drug developers at TIDES Europe 2026
Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website
43 drug developers are at TIDES Europe 2026 — 66 presentations on the program and 2 with a booth in the exhibit hall. Most represented: Novo Nordisk (6 on the program), Roche (5 on the program), AstraZeneca (4 on the program). 14 of them have their own page in this guide. As of Sep 25, 2026.
Focus
Top represented
Showing 1–12 of 43 organizations
| Organization | TIDES Europe 2026 Attendance |
|---|---|
Novo Nordisk Bagsværd, Denmark | |
Danish pharmaceutical company known for diabetes and obesity medicines, including the GLP-1 peptide drugs semaglutide and liraglutide. | Keynote Tue Nov 3 13:50–14:25 Next Generation GLP-1 Therapeutics How GLP-1 drugs for metabolic disease became longer-acting, and what it would take to dose them less often or swallow them as pills. PeptidesObesity & Metabolic Talk Wed Nov 4 08:05–08:35 Shifting Landscape: Global Regulatory CMC Guidance for Synthetic Oligonucleotides Where regulators around the world now agree and disagree on manufacturing and quality rules for synthetic oligonucleotides, and how those rules could align. Talk Thu Nov 5 09:05–09:35 Identity Testing of Synthetic Peptides: From Multi-Method Evaluation to a Compliant Two-Test Scheme Why two well-chosen laboratory tests can prove a manufactured peptide is the intended molecule, rather than the longer list of tests regulators expect. Talk Thu Nov 5 08:35–09:05 siRNA Conjugate Mediated Delivery to Disease Specific Cell Types Occurs through a Novel Mechanism How siRNA drugs attached to a carrier reach the cells behind chronic inflammatory disease and cancer, and how that route was worked out. Talk Fri Nov 6 09:10–10:00 Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for. Talk Fri Nov 6 08:40–09:10 Keynote Presentation: Decoding The Future of Obesity Care: The Signals Worth Paying Attention To Where obesity drug development stands in 2026 and which companies and market openings across Europe are worth watching. Talk Fri Nov 6 12:00–12:25 |
Roche Basel, Switzerland | |
Swiss pharmaceutical and diagnostics company with oligonucleotide and peptide programmes in its drug pipeline. | Chair Wed Nov 4 08:00–08:05 Talk Wed Nov 4 14:00–14:30 Enzymatic Ligation for the Production of Oligonucleotides Screening many ways to cut and rejoin siRNA strands with enzymes, then scaling the best one up for cleaner, higher-yield production. Talk Wed Nov 4 08:05–08:35 Shifting Landscape: Global Regulatory CMC Guidance for Synthetic Oligonucleotides Where regulators around the world now agree and disagree on manufacturing and quality rules for synthetic oligonucleotides, and how those rules could align. Talk Thu Nov 5 10:45–11:15 MCSGP Process Control and Characterization Strategy Keeping a multi-column peptide purification system dependable by working out which settings must stay within range to hold purity steady at full scale. Talk Thu Nov 5 11:15–11:45 Regulatory Insights from Recent Global Phase 3 Peptide Filings What health authorities asked about manufacturing, quality control and delivery devices during recent late-stage applications for peptide drugs. |
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company developing medicines across modalities, including oligonucleotide and peptide therapeutics. | Talk Thu Nov 5 15:00–15:30 Maintaining Diastereomeric Control in Phosphorothioate siRNAs: Integrated Analytical and Manufacturing Approaches for Reliable Clinical Development Why purifying siRNA can quietly shift the mix of mirror-image sulfur linkages between batches, and how to keep that mix steady. Talk Thu Nov 5 09:05–09:35 Peptide-Targeted Delivery of Oligonucleotide Therapeutics Early, pre-clinical work on a short peptide that steers gene-silencing drugs into the tissue where they are meant to act. Talk Thu Nov 5 09:05–09:35 Rethinking Green Credentials for Oligo Manufacturing Why simple waste-per-kilogram scores misjudge how green oligonucleotide production is, and what real improvement would involve. Talk Thu Nov 5 08:35–09:05 Systematic Route Design for Fragment-Based Peptide Synthesis: Enabling Liquid-Phase Transition A way to choose where to split a long peptide into fragments so it can be built in solution with better yield. |
Eli Lilly and Company Indianapolis, IN | |
Global pharmaceutical company whose peptide medicines include tirzepatide, with programs in oligonucleotide therapeutics. | Keynote Tue Nov 3 13:15–13:50 Making Oligonucleotides a High-Volume Reality: Next-Gen Platforms and Strategy for Oligonucleotide Manufacturing OligonucleotidesCMC & Manufacturing Keynote Tue Nov 3 14:25–15:00 Retatrutide: From Breakthrough Science to Global Medicine — The CMC Story Behind a Novel GIP, GLP-1, and Glucagon Receptor Agonist How the obesity and diabetes drug retatrutide is made at world supply scale by joining peptide fragments in solution with far less waste. PeptidesCMC & Manufacturing Talk Wed Nov 4 16:45–17:15 Made to Scale: What Tirzepatide's Manufacturing Challenge Teaches Us About Innovation Under Pressure Lessons from scaling up production of the diabetes and obesity drug tirzepatide, from an odd result at the bench to tonnes of material. Talk Thu Nov 5 16:00–16:30 Cycle Time Is a Quality Metric: Eloralintide from Discovery to Clinical Proof of Concept How the peptide eloralintide moved from discovery into patients by overlapping chemistry and biology cycles instead of running them one after another. |
Alnylam Pharmaceuticals Cambridge, MA | |
Develops and markets RNA interference (RNAi) therapeutics, including GalNAc-conjugated siRNA medicines for genetic, cardiometabolic and other diseases. | Talk Thu Nov 5 15:00–15:30 Genetically Validated Targets and the Next Wave of RNAi Therapeutics: Progress from the Alnylam Pipeline Progress in gene-silencing medicines at one company, including how human genetics points to new targets and what a broad pipeline has taught them. Talk Thu Nov 5 10:45–11:25 Part 1: siRELIS: A Convergent Enzymatic Ligation Strategy for siRNA Manufacturing; Part 2: Enzyme Development for Oligonucleotide Therapeutics Manufacturing Using engineered joining enzymes to assemble siRNA from short building blocks, and what scaling that approach taught two companies. |
Biogen Cambridge, MA | |
Biopharmaceutical company developing and marketing neuroscience medicines, including antisense oligonucleotide treatments. | Talk Wed Nov 4 10:15–10:45 Finding the Right Balance: How Formulation Aspects and Regulatory Expectations Affect Steam Sterilization of Antisense Oligonucleotide (ASO) Drug Products Whether antisense drug products can survive steam sterilisation, and how the liquid formula and container can be tuned so regulators accept it. Talk Thu Nov 5 08:05–08:35 Strategies for Implementing a Comprehensive Impurity Control Approach Across Oligonucleotide Purification Process A risk-based plan for clearing unwanted by-products, solvents and bacterial toxins from an oligonucleotide drug during two purification steps and filtration. |
CB Constructive Bio Cambridge, United Kingdom | |
Develops genetic code expansion technology to make proteins and peptides containing non-standard amino acids. | Talk Fri Nov 6 09:10–10:00 Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for. Talk Fri Nov 6 13:30–13:45 |
Ionis Pharmaceuticals Carlsbad, CA | |
Develops and markets antisense oligonucleotide medicines for neurological, cardiometabolic and rare diseases. | Talk Wed Nov 4 08:35–09:05 Regulatory CMC Strategies and Health Authority Interactions for Oligonucleotide Programs How manufacturing and quality filings for antisense drugs differ between the US and other regions, drawn from recent commercial applications. Talk Thu Nov 5 08:35–09:05 Moving Towards a Greener SPOS Process Practical ways to cut the environmental cost of oligonucleotide synthesis, including smaller wash volumes, new column designs and recycled solvent. |
Wave Life Sciences Cambridge, Massachusetts | |
Develops stereopure oligonucleotide medicines, including siRNA, antisense and RNA editing candidates. | Talk Wed Nov 4 09:05–09:35 Applying Small Molecule Drug Design Principles to Improve the Drug-like Properties of siRNA Designing siRNA the way chemists design small-molecule drugs, controlling each linkage to get lasting gene silencing in mouse liver and kidney. Talk Thu Nov 5 16:30–17:00 Synthesis and Characterization of Stereopure Chimeric Oligonucleotides Making and testing oligonucleotides in which every backbone link has one fixed mirror-image form, in small batches, to link structure to activity. |
Zealand Pharma Søborg, Denmark | |
Danish biotech developing peptide medicines for obesity and metabolic diseases, including amylin and GLP-1 analogues. | Talk Wed Nov 4 16:15–16:45 Dapiglutide: From Lab to Large Scale Manufacture through Innovative Peptide Process Development How process changes in making the peptide drug dapiglutide raised its overall yield from about 20% to over 60%. Talk Fri Nov 6 10:30–10:55 |
Develops oral treatments for obesity and metabolic disease, including a beaded glucose formulation that activates enteroendocrine cells. | Talk Fri Nov 6 09:10–10:00 Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for. |
Silence Therapeutics London, United Kingdom | |
Develops siRNA medicines using its mRNAi GOLD platform for cardiovascular, haematological and other diseases. | Talk Wed Nov 4 10:15–10:45 Elongating siRNA Duration of Action by Enhanced Nuclease Resistance: End Stabilization Revisited A modification near each end of a siRNA made gene silencing in mice last longer while needing fewer sulfur linkages. |
Instantly find 20 buyers from drug developers
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse TIDES Europe 2026 by
Organization type
Focus
Exhibit hall
Everyone
Not affiliated with or endorsed by Informa Connect or TIDES Europe. Submit a correction